Compare PICS & VIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PICS | VIR |
|---|---|---|
| Founded | 2012 | 2016 |
| Country | Brazil | United States |
| Employees | 4629 | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.5B |
| IPO Year | N/A | 2019 |
| Metric | PICS | VIR |
|---|---|---|
| Price | $10.51 | $9.30 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 7 |
| Target Price | ★ $22.00 | $19.43 |
| AVG Volume (30 Days) | 480.0K | ★ 1.6M |
| Earning Date | 05-30-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 17.49 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $68,556,000.00 |
| Revenue This Year | $33.65 | $270.22 |
| Revenue Next Year | $39.85 | N/A |
| P/E Ratio | $29.44 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $8.32 | $4.16 |
| 52 Week High | $18.49 | $11.66 |
| Indicator | PICS | VIR |
|---|---|---|
| Relative Strength Index (RSI) | 47.18 | 52.89 |
| Support Level | $9.99 | $8.40 |
| Resistance Level | $11.50 | $10.10 |
| Average True Range (ATR) | 0.96 | 0.45 |
| MACD | 0.17 | 0.07 |
| Stochastic Oscillator | 64.50 | 60.61 |
PicS NV is a digital payments company. The company operates a peer-to-peer (P2P) transfer platform that enables individuals to send money via mobile devices. It provides digital wallets, instant payments (Pix), P2P transfers, credit cards, loans, investments, insurance, and SMB payment solutions. The company has four reportable segments: Consumer Banking, Small and Medium-Sized Businesses, Audiences and Ecosystem Integration, and Institutional. The majority of the company's revenue is derived from the Consumer Banking segment, which generates revenue from various transaction activities occurring in the digital wallet, such as Pix, peer-to-peer (P2P) transfers, and bill payments.
Vir Biotechnology Inc is a clinical-stage biopharmaceutical company focused on powering the immune system by discovering and developing medicines for serious infectious diseases and cancer. The company uses its capabilities in antibody discovery and engineering, coupled with its proprietary AI engine dAIsY system, and the PRO-XTEN masking platform, to quickly and effectively discover and optimize potential new medicines. Its clinical development pipeline consists of investigational therapies like Tobevibart + elebsiran targeting the hepatitis delta virus (HDV), preclinical antibody candidates targeting HIV, and VIR-5500, VIR-5818, VIR-5525, and 7 PRO-XTEN programs targeting multiple solid tumors. Currently, the company generates revenue mainly by issuing license rights and through grants.